Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.75
NAS:PODD's Cash-to-Debt is ranked lower than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. NAS:PODD: 0.75 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:PODD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.03 Max: N/A
Current: 0.75
Equity-to-Asset 0.14
NAS:PODD's Equity-to-Asset is ranked lower than
94% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NAS:PODD: 0.14 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:PODD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.37  Med: 0.26 Max: 0.73
Current: 0.14
-2.37
0.73
Piotroski F-Score: 6
Altman Z-Score: 3.26
Beneish M-Score: -2.88
WACC vs ROIC
13.58%
-7.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -2.15
NAS:PODD's Operating Margin % is ranked lower than
64% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. NAS:PODD: -2.15 )
Ranked among companies with meaningful Operating Margin % only.
NAS:PODD' s Operating Margin % Range Over the Past 10 Years
Min: -402.65  Med: -23.18 Max: -2.15
Current: -2.15
-402.65
-2.15
Net Margin % -6.81
NAS:PODD's Net Margin % is ranked lower than
66% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. NAS:PODD: -6.81 )
Ranked among companies with meaningful Net Margin % only.
NAS:PODD' s Net Margin % Range Over the Past 10 Years
Min: -400.38  Med: -28.98 Max: -6.81
Current: -6.81
-400.38
-6.81
ROE % -53.68
NAS:PODD's ROE % is ranked lower than
85% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. NAS:PODD: -53.68 )
Ranked among companies with meaningful ROE % only.
NAS:PODD' s ROE % Range Over the Past 10 Years
Min: -178.71  Med: -81.74 Max: -49.42
Current: -53.68
-178.71
-49.42
ROA % -7.04
NAS:PODD's ROA % is ranked lower than
67% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. NAS:PODD: -7.04 )
Ranked among companies with meaningful ROA % only.
NAS:PODD' s ROA % Range Over the Past 10 Years
Min: -79.31  Med: -25.22 Max: -7.04
Current: -7.04
-79.31
-7.04
ROC (Joel Greenblatt) % -13.47
NAS:PODD's ROC (Joel Greenblatt) % is ranked lower than
67% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. NAS:PODD: -13.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:PODD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -310.53  Med: -128.33 Max: -13.47
Current: -13.47
-310.53
-13.47
3-Year Revenue Growth Rate 11.90
NAS:PODD's 3-Year Revenue Growth Rate is ranked higher than
80% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NAS:PODD: 11.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:PODD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 10.15 Max: 99.7
Current: 11.9
0
99.7
3-Year EPS without NRI Growth Rate -16.70
NAS:PODD's 3-Year EPS without NRI Growth Rate is ranked lower than
73% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NAS:PODD: -16.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:PODD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -71  Med: -20.15 Max: 31.2
Current: -16.7
-71
31.2
GuruFocus has detected 4 Warning Signs with Insulet Corp $NAS:PODD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PODD's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

PODD Guru Trades in Q2 2016

Jim Simons 620,892 sh (+179.18%)
Ken Fisher 16,963 sh (unchged)
Mariko Gordon Sold Out
PRIMECAP Management 5,189,472 sh (-0.09%)
Pioneer Investments 32,665 sh (-87.22%)
» More
Q3 2016

PODD Guru Trades in Q3 2016

Ron Baron 5,032 sh (New)
Ken Fisher 16,963 sh (unchged)
Pioneer Investments 32,665 sh (unchged)
PRIMECAP Management 5,179,572 sh (-0.19%)
Jim Simons 470,400 sh (-24.24%)
» More
Q4 2016

PODD Guru Trades in Q4 2016

Ken Fisher 16,963 sh (unchged)
Pioneer Investments 32,665 sh (unchged)
Ron Baron Sold Out
PRIMECAP Management 5,179,272 sh (-0.01%)
Jim Simons 127,000 sh (-73.00%)
» More
Q1 2017

PODD Guru Trades in Q1 2017

Joel Greenblatt 7,980 sh (New)
Jim Simons 148,700 sh (+17.09%)
Pioneer Investments 32,665 sh (unchged)
Ken Fisher 16,963 sh (unchged)
PRIMECAP Management 5,178,572 sh (-0.01%)
» More
» Details

Insider Trades

Latest Guru Trades with PODD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:OTCPK:ANSLY, NYSE:HAE, OTCPK:TOPCF, NYSE:CMD, NYSE:HYH, NAS:MMSI, NAS:ICUI, NAS:NXTM, NYSE:GKOS, NAS:NVCR, NAS:ATRI, NAS:LMNX, NAS:OSUR, NAS:IRTC, NAS:ATRC, NAS:ANGO, NAS:LMAT, NAS:MLAB, OTCPK:GMDTF, AMEX:CRHM » details
Traded in other countries:GOV.Germany,
Headquarter Location:USA
Insulet Corp is a medical device company that develops, manufactures and sells OmniPod Insulin Management System, an insulin infusion system for people with insulin-dependent diabetes.

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the OmniPod system, which consists of a small disposable insulin infusion device and a wireless personal diabetes manager that controls the dosage and has an integrated blood glucose meter. Since the OmniPod was approved by the U.S. Food and Drug Administration in 2005, more than 20,000 insulin-dependent diabetics in the United States have begun using it.

Top Ranked Articles about Insulet Corp

Weekly CEO Buys Highlights Insiders purchase shares of Sohu.com, Insulet, PJT, SiteOne and CoreSite
According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below: Read more...
Insulet Insider Invests in Company CEO purchases 40,000 shares
Insulet Corp. (PODD) CEO and Chairman Patrick Sullivan (Insider Trades) acquired 40,000 shares of the company on Dec. 2. The price was $33.89 per share for a total transaction of $1,355,600. Read more...

Ratios

vs
industry
vs
history
PB Ratio 37.95
PODD's PB Ratio is ranked lower than
98% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. PODD: 37.95 )
Ranked among companies with meaningful PB Ratio only.
PODD' s PB Ratio Range Over the Past 10 Years
Min: 3.13  Med: 16.05 Max: 1235
Current: 37.95
3.13
1235
PS Ratio 6.20
PODD's PS Ratio is ranked lower than
77% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. PODD: 6.20 )
Ranked among companies with meaningful PS Ratio only.
PODD' s PS Ratio Range Over the Past 10 Years
Min: 1.58  Med: 6.39 Max: 25.24
Current: 6.2
1.58
25.24
Price-to-Operating-Cash-Flow 508.84
PODD's Price-to-Operating-Cash-Flow is ranked lower than
96% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. PODD: 508.84 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PODD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 120.72  Med: 305.04 Max: 3931
Current: 508.84
120.72
3931
EV-to-EBIT -255.63
PODD's EV-to-EBIT is ranked lower than
99.99% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. PODD: -255.63 )
Ranked among companies with meaningful EV-to-EBIT only.
PODD' s EV-to-EBIT Range Over the Past 10 Years
Min: -281.7  Med: -25.4 Max: -1.1
Current: -255.63
-281.7
-1.1
EV-to-EBITDA 631.21
PODD's EV-to-EBITDA is ranked lower than
100% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. PODD: 631.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
PODD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -404.9  Med: -26.6 Max: 1906.1
Current: 631.21
-404.9
1906.1
Current Ratio 8.56
PODD's Current Ratio is ranked higher than
87% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. PODD: 8.56 )
Ranked among companies with meaningful Current Ratio only.
PODD' s Current Ratio Range Over the Past 10 Years
Min: 0.67  Med: 4.72 Max: 8.56
Current: 8.56
0.67
8.56
Quick Ratio 7.69
PODD's Quick Ratio is ranked higher than
89% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. PODD: 7.69 )
Ranked among companies with meaningful Quick Ratio only.
PODD' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.32 Max: 7.69
Current: 7.69
0.56
7.69
Days Inventory 63.92
PODD's Days Inventory is ranked higher than
89% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. PODD: 63.92 )
Ranked among companies with meaningful Days Inventory only.
PODD' s Days Inventory Range Over the Past 10 Years
Min: 32.97  Med: 52.65 Max: 111.63
Current: 63.92
32.97
111.63
Days Sales Outstanding 38.29
PODD's Days Sales Outstanding is ranked higher than
93% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. PODD: 38.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
PODD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.65  Med: 60.88 Max: 131.69
Current: 38.29
28.65
131.69
Days Payable 14.53
PODD's Days Payable is ranked lower than
79% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. PODD: 14.53 )
Ranked among companies with meaningful Days Payable only.
PODD' s Days Payable Range Over the Past 10 Years
Min: 14.53  Med: 46.8 Max: 65.48
Current: 14.53
14.53
65.48

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
PODD's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. PODD: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PODD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -354.5  Med: -13.6 Max: -0.9
Current: -1.5
-354.5
-0.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 111.50
PODD's Price-to-Tangible-Book is ranked lower than
99% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. PODD: 111.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PODD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.41  Med: 24.2 Max: 1123
Current: 111.5
3.41
1123
Price-to-Median-PS-Value 0.98
PODD's Price-to-Median-PS-Value is ranked higher than
55% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. PODD: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PODD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1 Max: 2.74
Current: 0.98
0.26
2.74
Earnings Yield (Greenblatt) % -0.39
PODD's Earnings Yield (Greenblatt) % is ranked lower than
69% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. PODD: -0.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PODD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.1  Med: 0 Max: 0
Current: -0.39
-5.1
0

More Statistics

Revenue (TTM) (Mil) $387.5
EPS (TTM) $ -0.46
Beta2.03
Short Percentage of Float9.99%
52-Week Range $27.62 - 48.23
Shares Outstanding (Mil)57.92

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 435 505 586
EPS ($) -0.34 0.03 0.11
EPS without NRI ($) -0.34 0.03 0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PODD

Headlines

Articles On GuruFocus.com
INSULET INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investi May 08 2017 
Weekly CEO Buys Highlights Dec 12 2016 
Insulet Insider Invests in Company Dec 06 2016 
Insulet Corporation to Announce Second Quarter 2015 Financial Results on July 30, 2015 Jul 08 2015 
Insulet Announces Organizational Changes Jun 30 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Insule Jun 26 2015 
Mariko Gordon's Trades In Q1 2015 Jun 12 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 24,400 Shares Feb 18 2011 
Insulet Corp. (PODD) President and CEO Duane Desisto sells 27,000 Shares Feb 15 2011 

More From Other Websites
Insulet Corp. breached its 50 day moving average in a Bearish Manner : PODD-US : May 24, 2017 May 24 2017
INSULET INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC... May 19 2017
Update in Lawsuit for Investors in NASDAQ: PODD Shares Against Insulet Corporation Announced by... May 17 2017
INSULET INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC... May 12 2017
Edited Transcript of PODD earnings conference call or presentation 8-May-17 8:30pm GMT May 10 2017
Insulet Pumps Out 25% Revenue Growth, Edges Up 2017 Guidance May 09 2017
INSULET INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC... May 08 2017
Insulet reports 1Q loss May 08 2017
Insulet Reports First Quarter 2017 Financial Results May 08 2017
Investor Network: Insulet Corporation to Host Earnings Call May 08 2017
Robbins Arroyo LLP: Insulet Corporation (PODD) Misled Shareholders According to a Class Action May 02 2017
Insulet Corp. – Value Analysis (NASDAQ:PODD) : April 28, 2017 Apr 28 2017
Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : April 27, 2017 Apr 27 2017
Is Medtronic's Artificial Pancreas the Next Big Thing in Diabetes? Apr 13 2017
​Medical device firm Insulet opening manufacturing site in Acton Apr 10 2017
ETFs with exposure to Insulet Corp. : April 7, 2017 Apr 07 2017
Insulet Corporation to Announce First Quarter 2017 Financial Results on May 8, 2017 Apr 07 2017
3 Top Diabetes Care Stocks to Buy in 2017 Mar 17 2017
When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17) Mar 16 2017
Insulet Corp. :PODD-US: Earnings Analysis: 2016 By the Numbers : March 2, 2017 Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}